European journal of medicinal chemistryOct 11, 2025

Design, creation, and testing of new diabetes drugs targeting PPAR receptors using a chemical group-focused approach

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated Apr 3, 2026

Abstract

Both novel compounds, 1d and 2d, significantly enhanced glucose uptake in adipocytes while exhibiting minimal adipogenic activity.

1d and 2d improved insulin resistance in models of type 2 diabetes.
HFD/STZ-induced diabetes models showed enhanced hepatic lipid metabolism with these compounds.
The compounds suppressed a specific phosphorylation in white adipose tissue linked to adverse effects.
Insulin-sensitizing genes, such as adiponectin, were upregulated by 1d and 2d.
Transcriptome analysis indicated selective modulation of PPAR signaling pathways without activating fat-producing gene programs.

Simplified

Peroxisome proliferator-activated receptor γ (PPARγ) full agonists are limited in clinical applications due to adverse effects-including adipogenesis and fluid retention-resulting from excessive activation. Using a functional group-oriented strategy, this study integrated structural features of GFT505-3d and ZLY06 to develop two novel compounds: the pan-PPAR agonist 1d and the PPARγ agonist 2d. Both compounds significantly enhanced glucose uptake in adipocytes while exhibiting minimal adipogenic activity. In HFD/STZ-induced type 2 diabetes mellitus (T2DM) models, 1d and 2d improved insulin resistance and hepatic lipid metabolism by suppressing PPARγ Ser273 phosphorylation in white adipose tissue and upregulating insulin-sensitizing genes such as adiponectin, without causing weight gain or fluid retention typically associated with conventional PPARγ agonists. Transcriptome analysis further confirmed their selective modulation of PPAR signaling pathways without activation of adipogenic gene programs. These findings highlight the unique dual regulatory advantages of 1d and 2d as next-generation PPAR modulators in glucose and lipid metabolism, offering novel insights for the design of PPAR-targeted anti-diabetic drugs.

Full Text

Full text is available at the source.

View Full Text ↗

Funding

Competing interests

Declaration of competing interest We declare that we have no financial and personal relationships with other people or organizations that can inappropriately influence our work. There is no professional or other personal interest of any nature or kind in any product, service and/or company that could be construed as influencing the position presented in, or the review of, the manuscript entitled.

PubMed

Design, creation, and testing of new diabetes drugs targeting PPAR receptors using a chemical group-focused approach

Abstract

Full Text

Funding

Competing interests

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Funding

Competing interests

Related papers

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief